JPMorgan Chase & Co. Raises Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

JPMorgan Chase & Co. lifted its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 103.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 85,545 shares of the biopharmaceutical company’s stock after acquiring an additional 43,470 shares during the quarter. JPMorgan Chase & Co. owned 0.13% of Celldex Therapeutics worth $2,162,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also modified their holdings of the stock. Vanguard Group Inc. lifted its position in shares of Celldex Therapeutics by 0.3% during the 4th quarter. Vanguard Group Inc. now owns 3,881,995 shares of the biopharmaceutical company’s stock worth $98,098,000 after purchasing an additional 12,213 shares during the last quarter. American Century Companies Inc. raised its stake in Celldex Therapeutics by 46.5% in the fourth quarter. American Century Companies Inc. now owns 608,457 shares of the biopharmaceutical company’s stock valued at $15,376,000 after buying an additional 193,093 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in Celldex Therapeutics by 1.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 544,330 shares of the biopharmaceutical company’s stock valued at $13,755,000 after buying an additional 5,474 shares in the last quarter. Fisher Asset Management LLC lifted its holdings in Celldex Therapeutics by 20.9% during the 4th quarter. Fisher Asset Management LLC now owns 452,497 shares of the biopharmaceutical company’s stock worth $11,435,000 after buying an additional 78,145 shares during the last quarter. Finally, Barclays PLC boosted its position in shares of Celldex Therapeutics by 140.7% during the 3rd quarter. Barclays PLC now owns 130,381 shares of the biopharmaceutical company’s stock worth $4,431,000 after acquiring an additional 76,207 shares in the last quarter.

Wall Street Analysts Forecast Growth

CLDX has been the subject of several research analyst reports. UBS Group assumed coverage on shares of Celldex Therapeutics in a report on Thursday, February 13th. They issued a “buy” rating and a $44.00 target price for the company. Morgan Stanley started coverage on Celldex Therapeutics in a research report on Thursday, March 20th. They issued an “overweight” rating and a $46.00 target price for the company. HC Wainwright reiterated a “buy” rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a research note on Friday, February 28th. The Goldman Sachs Group reduced their price target on shares of Celldex Therapeutics from $42.00 to $36.00 and set a “neutral” rating for the company in a research report on Monday, March 3rd. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $67.00 price objective on shares of Celldex Therapeutics in a research report on Wednesday, January 29th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $54.33.

Celldex Therapeutics Price Performance

Celldex Therapeutics stock opened at $19.43 on Thursday. Celldex Therapeutics, Inc. has a 12-month low of $14.40 and a 12-month high of $47.00. The stock has a market capitalization of $1.29 billion, a PE ratio of -7.56 and a beta of 1.59. The firm has a 50 day simple moving average of $19.33 and a 200-day simple moving average of $23.68.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, topping the consensus estimate of ($0.73) by $0.02. The business had revenue of $1.18 million during the quarter, compared to analyst estimates of $1.25 million. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. On average, analysts forecast that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current fiscal year.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.